My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 169

    1.

    Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

    Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA.

    Ann Intern Med. 1987 Jun;106(6):817-22.PMID: 3495213 [PubMed - indexed for MEDLINE]Related articles

    2.

    Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy.

    Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, Linehan WM, Rosenberg SA.

    J Urol. 1989 Mar;141(3):499-503.PMID: 2783983 [PubMed - indexed for MEDLINE]Related articles

    3.

    Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.

    Webb DE, Austin HA 3rd, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA.

    Clin Nephrol. 1988 Sep;30(3):141-5.PMID: 3263237 [PubMed - indexed for MEDLINE]Related articles

    4.

    Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion.

    Shalmi CL, Dutcher JP, Feinfeld DA, Chun KJ, Saleemi KR, Freeman LM, Lynn RI, Wiernik PH.

    J Clin Oncol. 1990 Nov;8(11):1839-46.PMID: 2230870 [PubMed - indexed for MEDLINE]Related articles

    5.

    A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al.

    N Engl J Med. 1987 Apr 9;316(15):889-97.PMID: 3493432 [PubMed - indexed for MEDLINE]Related articles

    6.

    Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma.

    Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, Matsunaga Y, Yamamoto Y.

    Hepatology. 1989 Sep;10(3):349-53.PMID: 2474481 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effects of interleukin-2 immunotherapy on renal function.

    Kozeny GA, Nicolas JD, Creekmore S, Sticklin L, Hano JE, Fisher RI.

    J Clin Oncol. 1988 Jul;6(7):1170-6.PMID: 3260620 [PubMed - indexed for MEDLINE]Related articles

    8.

    Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function.

    Palmieri G, Morabito A, Lauria R, Montesarchio V, Matano E, Memoli B, Libetta C, Rea A, Merola C, Correale P, et al.

    Eur J Cancer. 1993;29A(8):1119-22.PMID: 8518023 [PubMed - indexed for MEDLINE]Related articles

    9.

    Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.

    Marcus SL, Dutcher JP, Paietta E, Ciobanu N, Strauman J, Wiernik PH, Hutner SH, Frank O, Baker H.

    Cancer Res. 1987 Aug 1;47(15):4208-12.PMID: 3496958 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.

    Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al.

    J Natl Cancer Inst. 1993 Apr 21;85(8):622-32. Erratum in: J Natl Cancer Inst 1993 Jul 7;85(13):1091. PMID: 8468720 [PubMed - indexed for MEDLINE]Related articles

    11.

    Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

    Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA.

    Blood. 1987 Jun;69(6):1654-60.PMID: 3495302 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    [Immunotherapy of tumors using interleukin-2 and lymphokine-activated killer cells]

    Jost LM, Gmür J, Oelz O, Sauter C, Stahel RA.

    Schweiz Med Wochenschr. 1988 Feb 4;119(5):137-43. German. PMID: 3266369 [PubMed - indexed for MEDLINE]Related articles

    13.

    Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.

    Curti BD, Longo DL, Ochoa AC, Conlon KC, Smith JW 2nd, Alvord WG, Creekmore SP, Fenton RG, Gause BL, Holmlund J, et al.

    J Clin Oncol. 1993 Apr;11(4):652-60.PMID: 8257476 [PubMed - indexed for MEDLINE]Related articles

    14.

    The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

    Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg SA.

    Ann Intern Med. 1987 Sep;107(3):293-300.PMID: 3497595 [PubMed - indexed for MEDLINE]Related articles

    15.

    Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

    Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, et al.

    N Engl J Med. 1985 Dec 5;313(23):1485-92.PMID: 3903508 [PubMed - indexed for MEDLINE]Related articles

    16.

    The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cells.

    Kruit WH, Schmitz PI, Stoter G.

    Cancer Immunol Immunother. 1999 Sep;48(6):331-5.PMID: 10473808 [PubMed - indexed for MEDLINE]Related articles

    17.

    Short-duration in vitro interleukin-2-activated mononuclear cells for advanced cancer. A Hong Kong biotherapy pilot study trial.

    Yeung AW, Pang YK, Tsang YC, Wong SW, Leung JS.

    Cancer. 1993 Jun 1;71(11):3633-9.PMID: 8387882 [PubMed - indexed for MEDLINE]Related articles

    18.

    A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.

    Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM.

    J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):43-8.PMID: 8435431 [PubMed - indexed for MEDLINE]Related articles

    19.

    Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.

    Kuebler JP, Whitehead RP, Ward DL, Hemstreet GP 3rd, Bradley EC.

    J Urol. 1993 Sep;150(3):814-20. Review.PMID: 8345590 [PubMed - indexed for MEDLINE]Related articles

    20.

    A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.

    Eberlein TJ, Schoof DD, Jung SE, Davidson D, Gramolini B, McGrath K, Massaro A, Wilson RE.

    Arch Intern Med. 1988 Dec;148(12):2571-6.PMID: 3264142 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity